Description
Diridavumab, the alternative names CR6261, is a human monoclonal antibody direct against influenza A hemagglutinin. The CR6261 antibody was first discovered by the Scripps Institute and Crucell, a dutch biopharmaceutical company, and later developed by Janssen Pharmaceutical Companies of Johnson & Johnson under the trade name diridavumab. Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Catalog No.
DVV03801
Host species
Homo sapiens
Species reactivity
Influenza A virus
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
2.76 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, lambda
Applications
Research Grade Biosimilar
Target
HA/Hemagglutinin
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P03455
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
CR-6261, CR6261, CAS: 1393659-46-5, Influenza Virus (Flu)
Note
For research use only. Not suitable for clinical or therapeutic use.
關(guān)鍵字： Diridavumab;HA/Hemagglutinin;
武漢佰樂(lè)博生物（Biolab Reagents）由五位畢業(yè)于華中科技大學(xué)，華中農(nóng)業(yè)大學(xué)，武漢大學(xué)等知名高校，且具有二十年工作經(jīng)驗(yàn)的生命科學(xué)領(lǐng)域頂級(jí)研究者創(chuàng)立于2021年，憑借豐富的產(chǎn)品開(kāi)發(fā)經(jīng)驗(yàn)，利用全球領(lǐng)先的技術(shù)平臺(tái)，引進(jìn)和整合全球高品質(zhì)的蛋白、抗體和試劑盒產(chǎn)品。目前，佰樂(lè)博生物作為法國(guó)AntibodySystem在亞洲的獨(dú)家總代理，提供近30,000種生命科學(xué)試劑，核心產(chǎn)品涵蓋蛋白、抗體和試劑盒，旨在為科研工作者提供專業(yè)、全面、可靠的試劑支持，推動(dòng)生命科學(xué)研究的深入發(fā)展。